Table 1.
Study | N | EBRT Dose | Chemotherapy | Cetuximab | pCR Rate |
---|---|---|---|---|---|
MSKCC[38] | 20 | 50.4 Gy/1.8 Gy/5.5 wk | 5-FU IV CI, 225 mg/m2/d | 400 mg/m2 d 1, then 250 mg/m2 weekly | 12% |
Heibelberg[39] | 20 | 50.4 Gy/1.8 Gy/5.5 wk | Irinotecan, 40–50 mg/m2 (weekly) Capecitabine, 400–500 mg/m2 bid | 400 mg/m2 d 1, then 250 mg/m2 weekly | 7%* |
Louvain[40] | 40 | 45 Gy/1.8 Gy/5 wk | Capecitabine, 625–825 mg bid | 400 mg/m2/1 wk before RT, then 250 mg/m2 weekly during RT | 5% |
German Multisite Study[41] | 60 | 50.4 Gy/1.8 Gy/5.5 wk | Oxaliplatin, 50 mg/m2 (d1, 8, 22, 26) Capecitabine, 500–825 mg/m2 bid | 400 mg/m2/1 wk before RT, then 250 mg/m2 weekly during RT | 9% |
1/14 (7%) uT3 patients had a complete pathologic response whereas 4/5 (80%) uT2 patients had a complete pathologic response.
EBRT = external-beam radiation therapy; 5-FU = fluorouracil; MSKCC = Memorial Sloan-Kettering Cancer Center;
pCR = pathologic complete response; RT = radiation therapy.